Zimmer Biomet Holdings Inc (NYSE:ZBH) to Post Q1 2020 Earnings of $1.95 Per Share, Northcoast Research Forecasts

Zimmer Biomet Holdings Inc (NYSE:ZBH) – Equities research analysts at Northcoast Research increased their Q1 2020 EPS estimates for shares of Zimmer Biomet in a research note issued on Wednesday, November 6th. Northcoast Research analyst D. Keiser now forecasts that the medical equipment provider will post earnings per share of $1.95 for the quarter, up from their prior forecast of $1.93. Northcoast Research also issued estimates for Zimmer Biomet’s Q2 2020 earnings at $2.07 EPS, Q3 2020 earnings at $1.85 EPS, Q4 2020 earnings at $2.39 EPS and FY2020 earnings at $8.26 EPS.

Several other brokerages also recently commented on ZBH. Citigroup boosted their target price on shares of Zimmer Biomet from $146.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Robert W. Baird upgraded shares of Zimmer Biomet from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $132.00 to $154.00 in a research note on Monday, July 29th. Raymond James boosted their target price on shares of Zimmer Biomet from $150.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday. Stifel Nicolaus set a $155.00 target price on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Tuesday, September 17th. Finally, ValuEngine cut Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $147.95.

Shares of NYSE:ZBH traded up $2.07 on Friday, hitting $144.00. The stock had a trading volume of 997,802 shares, compared to its average volume of 1,183,991. Zimmer Biomet has a twelve month low of $96.99 and a twelve month high of $144.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.56 and a current ratio of 1.19. The firm’s 50 day moving average price is $136.99 and its 200-day moving average price is $128.52. The company has a market capitalization of $28.81 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 2.66 and a beta of 1.14.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $1.77 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.75 by $0.02. Zimmer Biomet had a negative net margin of 1.14% and a positive return on equity of 13.89%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the previous year, the company earned $1.63 EPS. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year.

A number of large investors have recently made changes to their positions in ZBH. Amundi Pioneer Asset Management Inc. grew its position in shares of Zimmer Biomet by 1.3% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 117,666 shares of the medical equipment provider’s stock worth $15,025,000 after buying an additional 1,465 shares during the period. Boltwood Capital Management grew its position in shares of Zimmer Biomet by 6.0% during the 2nd quarter. Boltwood Capital Management now owns 7,359 shares of the medical equipment provider’s stock worth $866,000 after buying an additional 415 shares during the period. Private Trust Co. NA acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth about $228,000. Fulton Bank N.A. acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth about $279,000. Finally, Carroll Financial Associates Inc. grew its position in shares of Zimmer Biomet by 7.4% during the 2nd quarter. Carroll Financial Associates Inc. now owns 2,977 shares of the medical equipment provider’s stock worth $350,000 after buying an additional 206 shares during the period. 87.72% of the stock is owned by hedge funds and other institutional investors.

In other Zimmer Biomet news, VP Chad F. Phipps sold 32,800 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $140.00, for a total transaction of $4,592,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Didier Deltort sold 360 shares of the business’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $139.25, for a total value of $50,130.00. Following the sale, the insider now directly owns 1,194 shares of the company’s stock, valued at $166,264.50. The disclosure for this sale can be found here. Insiders sold 40,244 shares of company stock valued at $5,621,885 over the last ninety days. 0.72% of the stock is currently owned by company insiders.

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date was Friday, September 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.67%. Zimmer Biomet’s dividend payout ratio is 12.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Further Reading: Support Level

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply